Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus

Cytometry Part B - Clinical Cytometry

Volumn 78, Issue 1, 2010, Pages 49-58

  Belouski, Shelley Sims ^a   Wallace, Daniel ^b   Weisman, Michael ^b   Ishimori, Mariko ^b   Hendricks, Lisa ^a   Zack, Debra ^a   Vincent, Mike ^a   Rasmussen, Erik ^a   Ferbas, John ^a   Chung, James ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cell; Immunophenotyping; Systemic lupus erythematosus

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD STORAGE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; B-LYMPHOCYTE SUBSETS; BLOOD PRESERVATION; DIAGNOSTIC ERRORS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REFERENCE STANDARDS; TIME FACTORS;

EID: 74849112382     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20482     Document Type: Article

References (43)

1. Mount GR, Gilliland WR. Emerging biological therapies in systemic lupus erythematosus. Clin Pharmacol Ther 2007;83:167-171.
2. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-4150.
3. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, Munafo A. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single-and repeated-dose study. Arthritis Rheum 2008;58:61-72.
4. Wallace D, Lisse J, Stohl W, McKay J, Boling E, Merrill J, Furie R, Petri M, Ginzler E, Chatham W, Fernandez V, Zhong J, Chevrier M, Freimuth M. Belimumab (LymphoStat-B) shows bioactivity and reduces SLE disease activity. Annual Congress of the European League Against Rheumatism (EULAR 2006). June 22, 2006. Oral Presentation #0029.
5. Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, St. Clair EW. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clinical Immunology 2007;123:235-243.
6. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: Which to choose and how to use. J Acquir Immune Defic Syndromes 1989;2:114-124.
7. Looney RJ, Anolik J, Sanz I. B cells as therpautic targets for rheumatic diseases. Curr Opin Rheumatol 2004;16:180-185.
8. Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-766.
9. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dorner T. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-1342.
10. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center b cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001;167:2361-2369.
11. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dorner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-5979.
12. Odendahl M, Keitzer R, Wahn U, Hiepe F, Radbruch A, Dorner T, Bunikowski R. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003;62:851-858.
13. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felger RE, Looney RJ, Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-3590.
14. Preparation ofcells from blood. In: Darzynkiewicz Z, Crissman HA, Robinson JP, editors. Methods in Cell Biology, 3rd ed. San Diego: Academic Press; 2001. pp 207-251.
15. Nicholson JK, Hubbard M, Jones BM. Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry. Cytometry 1996; 26:16-21.
16. Hultin LE, Matud J, Giorgi JV. Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. Cytometry 1998;33:123-132.
17. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993; 14:307-317.
18. Taylor JM, Cumberland WG, Meng X, Giorgi JV. Normal range estimation for repeated immunologic measures. Clin Diagn Lab Immunol 1996;3:139-142.
19. Ferbas J, Schroeder M. Using flow cytometers to enable translational medicine programs. Am Drug Discov 2008;3:39-47.
20. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003;112:1506-1520.
21. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971;50:85-95.
22. Wentworth J, Davies C. Systemic lupus erythematosus. Nat Rev Drug Discov 2009;8:103-104.
23. Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann NY Acad Sci 2005; 1050:124-133.
24. Crow MK. Fast forward for systemic lupus erythematosus clinical trials. Nat Clin Pract Rheum 2008;4:387.
25. Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): Lessons from the past as we proceed to the future - The EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 2008;17:437-442.
26. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.[ see comment]. Ann Rheum Dis 2008;67:195-205.
27. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, et al. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 2007;7:131-139.
28. Ashmore LM, Shopp GM, Edwards BS. Lymphocyte subset analysis by flow cytometry Comparison of three different staining techniques and effects of blood storage. J Immunol Methods 1989;118: 209-215.
29. Appay V, Reynard S, Voelter V, Romero P, Speiser DE, Leyvraz S. Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods 2006;309:192-199.
30. Ekong T, Kupek E, Clark C, Davies A, Pinching A. Technical influences on immunophenotyping by flow cytometry. The effect of time and temperature of storage ont he viability of lymphocyte subsets. J Immunol Methods 1993;164:263-273.
31. Schumacher MJ, Burkhead T. Stability of fresh and preserved fetal and adult lymphocyte cell surface markers. J Clin Lab Anal 2000;14: 320-326.
32. Kyu SY, Kobie J, Yang H, Zand MS, Topham DJ, Quataert SA, et al. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. J Immunol Methods 2009;340:42-47.
33. Rao C, Rutner H, Hermann M, Russell T, Terstappen L. Preservative of blood specimens to prevent breakdown of circulating tumor cells. Proc Am Assoc Cancer Res 2002;43:734-735.
34. Woywodt A, Blann A, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, et al. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: Proposal of a definition and a consensus protocol. J Thromb Haemost 2006;4:671-677.
35. Agematsu K, Nagumo H, Oguchi Y, Nakazawa T, Fukushima K, Yasui K, et al. Generation of plasma cells from peripheral blood memory B cells: Synergistic effect of interleukin-10 and CD27/ CD70 interaction. Blood 1998;91:173-180.
36. Agematsu K, Hokibara S, Nagumo H, Shinozaki K, Yamada S, Komiyama A. Plasma cell generation from B-lymphocytes via CD27/ CD70 interaction. Leuk Lymp 1999;35:219-225.
37. Jacquot S, Kobata T, Iwata S, Morimoto C, Schlossman SF. CD154/ CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: Enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997;159:2652-2657.
38. Shi Y, Agematsu K, Ochs HD, Sugane K. Funtional analysis of human memory B-cell subpopulations: IgD+CD27+ B cells are crucial in secondary immune responses by producing high affinity IgM. Clin Immunol 2003;108:128-137.
39. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-6643.
40. Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 1986;29:739-747.
41. Belouski SS, Rasmussen HE, Thomas JK, Ferbas J, Zack DJ Changes in B cells and B cell subsets induced by BAFF neutralization in vivo [abstract]. Arthritis Rheum 2007;48:s565.
42. Nicholas MW, Dooley MA, Hogan SL, Anolik J, Looney J, Sanz I, et al. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol 2008; 126:189-201.
43. Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol 2001;167:3610-3618.